Poland· PL-100488530
Tevimbra
A tislelizumab product containing tislelizumabum, registered in Poland by BeiGene Ireland Ltd.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tislelizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF09 (tislelizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Tislelizumab · ATC L01FF09
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of tislelizumab costs, country by country.
Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tislelizumab · price per daily dose (9.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$204.40
The record
At a glance
URPL (Poland)- Active substance
- Tislelizumabum
- Manufacturer
- BeiGene Ireland Ltd.
- Country
- Poland (PL)
- ATC code
- L01FF09
- ATC class
- Tislelizumab
- Defined daily dose
- 9.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08720598340280
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tislelizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTEVIMBRABeOne Medicines USA, Inc.
- CzechiaTEVIMBRABeOne Medicines Ireland Limited, Dublin
- BelgiumTevimbra 100 mgBeOne Medicines Ireland
- FinlandTevimbraBeOne Medicines Ireland Limited
- SwitzerlandTevimbra 100 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungBeOne Medicines I GmbH
- FranceTEVIMBRA 100 mg, solution à diluer pour perfusionBEONE MEDICINES IRELAND (IRLANDE)
- IrelandTevimbra 100 mg concentrate for solution for infusionBeiGene Ireland Limited
- IcelandTevimbraBeigene Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tevimbra
- Norway · Tevimbra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/85b1125e-92b0-4a16-be03-372b9adddd53 GET /v1/drugs/85b1125e-92b0-4a16-be03-372b9adddd53?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg/ml",
"packaging": "Rpz ¦ EU/1/23/1758/002 ¦ 151709\n2 fiol. 10 ml\n08720598340280 ¦ Rpz ¦ EU/1/23/1758/001 ¦ 161419\n1 fiol. 10 ml",
"substance": "Tislelizumabum 10 mg/ml",
"common_name": "Tislelizumabum",
"pl_product_id": "100488530",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tislelizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.